FBRX · Insider Trading
Forte Biosciences, Inc. Common Stock
Every open-market purchase and sale reported by FBRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-27 | Richard G Vincent | Director | D | −51,353 deriv. | — |
| 2026-08-27 | Shivpreet Singh Kapoor | Director | D | −51,353 deriv. | — |
| 2026-08-27 | David W Gryska | Director | U | −5,940 | — |
| 2026-08-27 | Scott C. Brun | Director | D | −54,353 deriv. | — |
| 2026-08-27 | Antony A Riley | CHIEF FINANCIAL OFFICER | U | −42,600 | — |
| 2026-08-27 | Barbara K Finck | Director | D | −60,519 deriv. | — |
| 2026-08-27 | Stephen K Doberstein | Director | D | −55,353 deriv. | — |
| 2026-08-27 | Paul A. Wagner | SEE REMARKS | U | −85,482 | — |
| 2026-08-27 | Steven Kornfeld | Director | U | −3,960 | — |
| 2026-07-06 | Antony A Riley | CHIEF FINANCIAL OFFICER | MIXED | +241 | −$2.86K |
| 2026-07-06 | Paul A. Wagner | SEE REMARKS | MIXED | +1,152 | −$2.09K |
| 2026-06-17 | Antony A Riley | CHIEF FINANCIAL OFFICER | A | +22,000 deriv. | — |
| 2026-06-17 | Paul A. Wagner | SEE REMARKS | A | +500,000 deriv. | — |
| 2026-06-02 | Richard G Vincent | Director | A | +18,353 deriv. | — |
| 2026-06-02 | Shivpreet Singh Kapoor | Director | A | +18,353 deriv. | — |
| 2026-06-02 | Steven Kornfeld | Director | A | +18,353 deriv. | — |
| 2026-06-02 | Scott C. Brun | Director | A | +18,353 deriv. | — |
| 2026-06-02 | Stephen K Doberstein | Director | A | +18,353 deriv. | — |
| 2026-06-02 | David W Gryska | Director | A | +18,353 deriv. | — |
| 2026-04-03 | Paul A. Wagner | SEE REMARKS | MIXED | +1,152 | −$2.44K |
| 2026-04-03 | Antony A Riley | CHIEF FINANCIAL OFFICER | MIXED | +241 | −$3.33K |
| 2026-01-13 | Antony A Riley | CHIEF FINANCIAL OFFICER | A | +150,000 deriv. | — |
| 2026-01-13 | Paul A. Wagner | SEE REMARKS | A | +450,000 deriv. | — |
| 2026-01-02 | Paul A. Wagner | SEE REMARKS | MIXED | +1,086 | −$4.47K |
| 2026-01-02 | Antony A Riley | CHIEF FINANCIAL OFFICER | MIXED | +9,901 | +$250.63K |
| 2025-10-02 | Paul A. Wagner | SEE REMARKS | MIXED | +1,152 | −$1.42K |
| 2025-10-02 | Antony A Riley | CHIEF FINANCIAL OFFICER | MIXED | +241 | −$1.95K |
| 2025-07-03 | Paul A. Wagner | SEE REMARKS | MIXED | +1,152 | −$1.22K |
| 2025-07-03 | Antony A Riley | CHIEF FINANCIAL OFFICER | MIXED | +241 | −$1.67K |
| 2025-04-02 | Paul A. Wagner | SEE REMARKS | MIXED | +1,232 | −$134 |
| 2025-04-02 | Antony A Riley | CHIEF FINANCIAL OFFICER | MIXED | +221 | −$1.14K |
| 2025-03-21 | Barbara K Finck | Director | A | +31,000 deriv. | — |
| 2025-03-21 | Scott C. Brun | Director | A | +31,000 deriv. | — |
| 2025-03-21 | Steven Kornfeld | Director | A | +31,000 deriv. | — |
| 2025-03-21 | Richard G Vincent | Director | A | +31,000 deriv. | — |
| 2025-03-21 | Shivpreet Singh Kapoor | Director | A | +31,000 deriv. | — |
| 2025-03-21 | Antony A Riley | CHIEF FINANCIAL OFFICER | A | +323,000 deriv. | — |
| 2025-03-21 | Stephen K Doberstein | Director | A | +31,000 deriv. | — |
| 2025-03-21 | David W Gryska | Director | A | +31,000 deriv. | — |
| 2025-03-21 | Paul A. Wagner | SEE REMARKS | A | +920,000 deriv. | — |
| 2025-01-02 | Antony A Riley | CHIEF FINANCIAL OFFICER | MIXED | +221 | −$3.50K |
| 2025-01-02 | Paul A. Wagner | SEE REMARKS | MIXED | +1,086 | −$3.72K |
| 2024-11-22 | Antony A Riley | CHIEF FINANCIAL OFFICER | Buy | +22,514 | +$125.00K |
| 2024-10-02 | Paul A. Wagner | SEE REMARKS | MIXED | +1,152 | −$506 |
| 2024-10-02 | Antony A Riley | CHIEF FINANCIAL OFFICER | MIXED | +242 | −$686 |
| 2024-09-19 | Shivpreet Singh Kapoor | Director | A | +2,000 deriv. | — |
| 2024-09-19 | Richard G Vincent | Director | A | +2,000 deriv. | — |
| 2024-08-22 | Scott C. Brun | Director | A | +50,000 deriv. | — |
| 2024-08-22 | Lawrence Eichenfield | Director | A | +50,000 deriv. | — |
| 2024-08-22 | David W Gryska | Director | A | +50,000 deriv. | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FBRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.